Skip to main content
. 2021 Feb 5;32(3):723–735. doi: 10.1681/ASN.2020050598

Table 1.

Patients characteristics and baseline data (FAS) stratified by two factors

Characteristics Factor 1 Factor 2
LC, n=62 SO, n=53 Standard Control, n=57 Strict Control, n=58
No. (women) 62 (21) 53 (17) 57 (20) 58 (18)
Age, yr 62.9±10.1 60.7±11.0 61.3±10.6 62.4±10.5
CACs 680 [340–2418] 824 [224–1513] 891 [257–1581] 711 [319–2270]
Phosphate, mg/dl 5.98±1.16 6.00±0.75 6.04±1.16 5.95±0.80
Calcium, mg/dl 8.74±0.70 8.91±0.69 8.90±0.67 8.73±0.71
Magnesium, mg/dl 2.56±0.35 2.64±0.37 2.59±0.39 2.61±0.33
TSAT, % 27.4±12.4 22.6±9.0 23.8±10.9 26.6±11.5
Ferritin, ng/ml 71 [39–126] 59 [29–135] 45 [30–114] 89 [35–146]
Intact PTH, pg/ml 137 [99–187] 124 [88–178] 132 [105–216] 130 [84–179]
Intact FGF-23, pg/ml 5225 [2595–12,325] 5275 [2258–10,600] 6840 [2772–13,800] 4395 [2070–10,325]
Past history of CVD, % 25.8 43.4 35.1 32.8
Diabetes mellitus, % 38.7 50.9 38.6 50.8
Dyslipidemia, % 45.2 43.4 45.6 43.1
Hypertension, % 90.3 84.9 91.2 84.5
Active vitamin D prescription, % 66.1 66.0 68.4 64.0
Calcimimetics prescription, % 35.5 32.1 38.6 29.3

Data are on the basis of full set analysis. Continuous variables are presented as mean ± SD or median [IQR]. Active vitamin D included oral calcitriol, alfacalcidol, and intravenous maxacalcitol and calcitriol.